Pheochromocytoma, Paraganglioma
Conditions
Keywords
Pheochromocytoma, Paraganglioma, dysglycemia
Brief summary
The investigators will retrospectively analyze the clinical data of consecutive patients with pheochromocytomas and paragangliomas admitted between January 2018 and June 2020. The clinical characteristics of patients with and without dysglycemia will be compared, and whether surgery could improve the patients'dysglycemia will be also investigated.
Detailed description
This retrospective cohort study will include all consecutive adult patients who underwent surgery for PHEOs and catecholamine-secreting PGLs from January 2018 to June 2020. Patients with recurrent PPGLs, those who required steroids after adrenalectomy, and those with inadequate clinical records were excluded. The patients' electronic medical files were reviewed. Patients with dysglycemia included those with diabetes, or impaired fasting glucose, or impaired glucose tolerance. Clinical history data such as age, sex, body mass index (BMI), the presence of preoperative symptoms, biochemical test results, and tumor characteristics, such as tumor diameters and locations were extracted and analyzed.
Interventions
OTHERCatecholamines
Focus on whether catecholamine exposure is associated with dysglycemia in patients with pheochromocytoma and paraganglioma
Sponsors
Peking Union Medical College Hospital
China National Center for Cardiovascular Diseases
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* age ≥18 years old * patients with surgical pathological diagnosis of pheochromocytomas and paragangliomas(PPGLs)
Exclusion criteria
* recurrent PPGLs * patients who required steroids after adrenalectomy * patients with inadequate clinical records were excluded.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline OGTT（oral glucose tolerance test）results to 6-12 months after surgery | Baseline, 6-12 months after surgery | OGTT results （including fasting blood glucose in the text, blood glucose results at 2 hours after oral administration of 75g glucose）at baseline and 6-12 months after surgery will be recorded to assess the effect of surgery on dysglycemia |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| random blood glucose results | baseline, 6-12 months after surgery | random blood glucose results at baseline and 6-12 months after surgery will be recorded to assess the effect of surgery on dysglycemia |
| HbA1c | baseline, 6-12 months after surgery | HbA1c results at baseline and 6-12 months after surgery will be recorded to assess the effect of surgery on dysglycemia |
| fasting blood glucose | baseline, 6-12 months after surgery | fasting blood glucose results at baseline and 6-12 months after surgery will be recorded to assess the effect of surgery on dysglycemia |
Countries
China
Outcome results
None listed